Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2021 | What’s next for dark matter as a biomarker for Alzheimer’s disease?

Satya VVN Kothapalli • 12 Mar 2021
AD/PD 2021
Alzheimer’s Disease

Brain dark matter, identified using quantitative Gradient Recalled Echo (qGRE) MRI, can be a valuable in vivo biomarker for early detection of Alzheimer’s disease. Satya VVN Kothapalli, PhD, Washington University in St. Louis, St. Louis, MO, discusses the next steps going forward for the investigation of brain dark matter as a new biomarker of neurodegeneration in Alzheimer’s disease. This interview took place during the AD/PD™ 2021 conference.

More from Satya VVN Kothapalli

Roles of ultrasound in Alzheimer’s disease diagnosis and therapy
3:07
Roles of ultrasound in Alzheimer’s disease diagnosis and therapy
Satya VVN Kothapalli • 12 Mar 2021
Advantages of qGRE MRI for early diagnosis of Alzheimer's disease
3:22
Advantages of qGRE MRI for early diagnosis of Alzheimer's disease
Satya VVN Kothapalli • 12 Mar 2021
Brain dark matter: a biomarker for early detection of Alzheimer's disease
9:18
Brain dark matter: a biomarker for early detection of Alzheimer's disease
Satya VVN Kothapalli • 12 Mar 2021

Related Videos

PCSK9-targeted therapies and the risk of stroke and dementia: a meta-analysis of RCTs
3:34
PCSK9-targeted therapies and the risk of stroke and dementia: a meta-analysis of RCTs
Vikash Jaiswal • 26 Aug 2026
How AI and data science are advancing obstructive sleep apnea management
2:23
How AI and data science are advancing obstructive sleep apnea management
Omonigho Michael Bubu • 15 Jun 2026
Obstructive sleep apnea and Alzheimer's disease risk: toward personalized care
5:40
Obstructive sleep apnea and Alzheimer's disease risk: toward personalized care
Omonigho Michael Bubu • 15 Jun 2026
The future of personalized Parkinson's disease care considering differing subtypes
3:10
The future of personalized Parkinson's disease care considering differing subtypes
Massimiliano Passaretti • 28 Jun 2026

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJNeurology is intended for healthcare professionals